STI Stock Trade Intelligence
TRI

TRIVARX LTD

Health Care · ASX:TRI
$0.0100
▲ +11.11%
Market cap
$12M
Turnover
$102,177
Last price
$0.0100
Day change
+11.11%
Announcements
12
Range, past year
Open 0.021 · Low 0.007 · Now 0.010 · High 0.035
Open TRI in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

TRI momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
35/100
Wyckoff phase
Accumulation32d
Trend stage
Neutral
1 Day
+11.1%
1 Week
+0.0%
1 Month
+11.1%
1 Year
-52.4%
RSI
52
Avg daily range
7.9%

TRIVARX LTD scores 35 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 32 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -56.2%
  • High volatility (ATR 7.9%)
  • Risk rating: Very High
  • Composite downside risk elevated
TRI appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

TRI announcements

Recent price-sensitive releases.
  • 2026-11-11 TrivarX Appoints Emeritus Research for Phase 1 Study Progress Report
  • 2026-10-30 September 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-22 Syntro Health Appointed to Support Stabl-Im Clinical Program Progress Report
  • 2026-09-23 Stabl-Im Clinical Development Update Progress Report
  • 2026-08-27 Appendix 4E - Preliminary Final Report Preliminary Final Report
  • 2026-07-28 June 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-16 Stabl-Im clinical trial supply milestone achieved
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.